The U.S. Food and Drug Administration (FDA) has approved Armlupeg (pegfilgrastim-unne) 6 milligrams per 0.6 milliliter (mg/mL ...

India-based firm Lupin has joined the pegfilgrastim parade with the FDA’s approval of Armlupeg (pegfilgrastim-unne), the ...

Lupin receives USFDA approval for Armlupeg, a biosimilar to Neulasta, enhancing treatment options for cancer patients.

Neulasta Delivery Kit Provides Administration Option for Patients who may not Otherwise Need to Return to Clinic or Hospital the day After Chemotherapy One of the most common side effects of ...

The Food and Drug Administration approves Nyvepria, the biosimilar to Neulasta, to help treat and prevent infections in patients undergoing myelosuppressive chemotherapy. The Food and Drug ...

Armlupeg is indicated to reduce infection risk, specifically febrile neutropenia, in non-myeloid cancer patients.

Stimufend ® (pegfilgrastim-fpgk), a biosimilar to Neulasta ® (pegfilgrastim), has been made available by Fresenius Kabi. Stimufend, a leukocyte growth factor, is indicated to decrease the incidence of ...

The FDA has approved pegfilgrastim-unne (Armlupeg) for the treatment of patients with nonmyeloid cancers undergoing treatment ...

Lupin has received USFDA approval for its biosimilar Armlupeg (pegfilgrastim-unne) injection, to be manufactured at its Pune ...

The front page of the Feb. 26 Gazette featured an article on the extraordinary cost of cancer treatment. However, the article failed to discuss any potential solutions, such as the ability to lower ...

Neulasta Delivery Kit Provides Administration Option for Patients who may not Otherwise Need to Return to Clinic or Hospital the day After Chemotherapy THOUSAND OAKS, Calif., March 2, 2015 /PRNewswire ...

Credit: Getty Images. A biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product. Fylnetra ™ ...